BioTheranostics, Ferrer InCode Ink Distribution Pact | GenomeWeb

NEW YORK (GenomeWeb News) – BioMerieux subsidiary BioTheranostics said today that it has signed up Spain's Ferrer InCode to market its molecular diagnostic cancer test in Spain, Portugal, Greece, and Venezuela.

Under the agreement, Ferrer InCode will market BioTheranostics’ Theros CancerTYPE ID molecular cancer classifier. The test is a 92-gene assay that oncologists may use in their efforts to manage patients whose primary tumor sites are not known, otherwise known as cancers of unknown primary origin, or CUP.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.